Atherosclerosis and its complications are responsible for about 40% of deaths in the developed world and for about 30% of fatalities in developing nations.However, despite the consistent effects of lipid-lowering medications in reducing cardiovascular morbidity and mortality, the reductions in clinical events remain modest, ranging from 25 to 35%. In addition to lipid modification, blockade of renin angiotensin system, reduction of oxidative stress, augmentation of nitric oxide availability, reduction of Ca2+ influx as well as attenuation of inflammation, platelet activation, smooth muscle...